Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer
This study evaluates whether sunitinib and pazopanib treatments are associated with change in skeletal muscle area (SMA) and total lean body mass (LBM) as well as to compare their efficacies and safety profiles in patients with metastatic renal cell cancer (mRCC).01/29/2019
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
More News: Cancer | Cancer & Oncology | Kidney Cancer | Renal Cell Carcinoma | Study | Urology & Nephrology